文献速递肝胆胰外科围术期管理与 ERAS

改良衰弱指数与肝移植术后结局:多中心队列研究

Modified Frailty Index and outcomes after liver transplantation: A multicenter cohort study.
PubMed 文献 · Surgery · 2026-05-15

基于TriNetX美国协作网络2015-2025年13408例成人肝移植受者,按5变量改良衰弱指数分为非衰弱、中度衰弱和重度衰弱三组,经倾向性评分匹配后分析发现,衰弱组30天术后并发症复合结局显著更高,重度衰弱与5年死亡率升高相关。

要点

  • 改良衰弱指数可对肝移植术后短期和长期风险进行分层。
  • 中度及重度衰弱均与30天并发症复合结局显著升高相关。
  • 重度衰弱与5年全因死亡率升高相关,中度衰弱无显著差异。

核心结论

  • 改良衰弱指数5可对肝移植术后短期和长期风险进行分层,衰弱与并发症、排斥反应和晚期死亡率升高相关,支持将其纳入移植前评估和围术期规划。

研究设计与样本

  • 多中心回顾性队列研究,纳入TriNetX美国协作网络2015-2025年 registry 中接受原位肝移植的成人受者13408例。
  • 按改良衰弱指数分为非衰弱(评分0-1)、中度衰弱(评分2)和重度衰弱(评分≥3)三组,并使用倾向性评分匹配平衡人口学、合并症和MELD组分。

主要发现

  • 改良衰弱指数2分析有2678对匹配患者,改良衰弱指数≥3分析有1782例匹配患者。
  • 30天并发症复合结局在改良衰弱指数2组为55.9% vs 49.1%(OR 1.32,95%CI 1.20-1.44),在改良衰弱指数≥3组为57.4% vs 49.3%(OR 1.39,95%CI 1.24-1.54)。
  • 扩展复合结局(含感染和手术并发症)在两组中均仍显著更高。
  • 衰弱组90天死亡率更低(改良衰弱指数2:HR 0.54,95%CI 0.39-0.76;改良衰弱指数≥3:HR 0.51,95%CI 0.34-0.75)。
  • 5年时,改良衰弱指数≥3与死亡率升高相关(HR 1.29,95%CI 1.07-1.54),而改良衰弱指数2与5年死亡率无显著差异。

临床怎么用

  • 可将改良衰弱指数5纳入肝移植术前评估,识别术后并发症高风险患者并优化围术期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty has historically been associated with worse transplant outcomes. We hypothesized that higher scores on the 5-variable Modified Frailty Index would be associated with worse morbidity. METHODS: We included adults in the TriNetX US Collaborative Network (2015-2025) registry who underwent orthotopic liver transplantation. Patients were stratified into 3 groups based on the Modified Frailty Index: nonfrail (score 0-1), moderately frail (score 2), and severely frail (score ≥3). Propensity score matching balanced demographics, comorbidities, and model for end-stage liver disease components. The primary outcome was 30-day postoperative morbidity, defined as a composite outcome. A sensitivity analysis used an expanded composite that included infections and surgical complications. Secondary outcomes included all-cause mortality at 90 days and 1, 3, and 5 years; acute rejection; and graft failure. RESULTS: Among 13,408 recipients, 4,667 were nonfrail, 4,987 were moderately frail, and 3,751 were severely frail. There were 2,678 matched pairs in the Modified Frailty Index 2 analysis and 1,782 matched patients in the Modified Frailty Index ≥3 analysis. Composite morbidity was significantly higher in both frail groups: 55.9% vs 49.1% (odds ratio, 1.32; 95% confidence interval, 1.20-1.44) among Modified Frailty Index 2, and 57.4% vs 49.3% (odds ratio, 1.39; 95% confidence interval, 1.24-1.54) among Modified Frailty Index ≥3. The expanded composite remained significantly higher in both groups. Frail recipients had lower 90-day mortality (Modified Frailty Index 2: hazard ratio, 0.54; 95% confidence interval, 0.39-0.76; Modified Frailty Index ≥3: hazard ratio, 0.51; 95% confidence interval, 0.34-0.75). By 5 years, Modified Frailty Index ≥3 was associated with higher mortality (hazard ratio, 1.29; 95% confidence interval, 1.07-1.54), whereas Modified Frailty Index 2 was not associated with a significant difference in 5-year mortality. CONCLUSION: Modified Frailty Index 5 stratifies short-term and long-term risk after liver transplantation. Frailty was associated with significantly greater morbidity, rejection, and late mortality, supporting its integration into pretransplant evaluation and perioperative planning.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Abuassi M, Turner T, Westein R, et al. Modified Frailty Index and outcomes after liver transplantation: A multicenter cohort study. Surgery. 2026. PMID: 42139821. doi:10.1016/j.surg.2026.110235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。